Join
Live feed
·
PRReleasevia Quantisnow
Forte Biosciences Inc. logo

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

ByQuantisnow·Wall Street's wire, on your screen.
FBRX· Forte Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBRX (Forte Biosciences Inc.) and more on Quantisnow.